华纳药厂：致根医药研发的ZG-002片Ⅰ期临床试验已完成

Core Viewpoint - Warner Pharmaceuticals announced the completion of Phase I clinical trials for ZG-002, a novel drug developed by its affiliate, Digen Pharmaceuticals, aimed at treating moderate to severe plaque psoriasis [1] Group 1: Clinical Trial Results - The clinical trial results indicate that ZG-002 has good safety and tolerability after both single and multiple doses within the explored dosage range, with no serious adverse events reported [1] - Pharmacokinetic characteristics of ZG-002 are clearly defined, showing that blood concentration and exposure levels increase with the dosage [1] - The trial results also demonstrate a decrease in IFN-γ levels with increased drug exposure, suggesting potential therapeutic efficacy of ZG-002 for moderate to severe psoriasis [1]